Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02420860 · ClinicalTrials.gov registry record · Phase 2
Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
A Phase 2 study of Plasma Cell Myeloma and Hematopoietic Cell Transplantation Recipient, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 113
- Enrollment target
- 1
- Study location
NCT02420860: Active Phase 2 study of Plasma Cell Myeloma and Hematopoietic Cell Transplantation Recipient, sponsored by M.D. Anderson Cancer Center.
NCT02420860 is a Phase 2 study of Plasma Cell Myeloma and Hematopoietic Cell Transplantation Recipient that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 113 participants, below the 205-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02420860, a Phase 2 study of Plasma Cell Myeloma and Hematopoietic Cell Transplantation Recipient, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 113 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well elotuzumab works when given with lenalidomide as maintenance therapy after transplant in patients with newly diagnosed multiple myeloma who underwent transplant using their own stem cells (autologous transplant). Maintenance therapy is treatment that is given to help keep cancer from coming back after it has disappeared following the initial treatment. Immunotherapy with monoclonal antibodies, such as elotuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Biological therapies, such as lenalidomide, may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Adding elotuzumab to standard maintenance therapy with lenalidomide may work better in treating patients with multiple myeloma who have undergone transplant.
Primary Outcome
Will be estimated using the Kaplan-Meier method. The log-rank test will be performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model may be used to include multiple covariates in the time-to-event analysis.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- DRUG Lenalidomide
- BIOLOGICAL Elotuzumab
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2015-04-14 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 2 |
What the registry record for NCT02420860 still lists
NCT02420860 is an interventional study that assigns participants to a tested intervention. The registered 113 participants enrollment target is mid-sized for trials with a published cap, below the 205-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (45% lower).
The record links to 2 conditions, with Plasma Cell Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Questionnaire Administration is the first listed.
NCT02420860 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02420860 about?
NCT02420860 is a clinical study titled "Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma". This phase II trial studies how well elotuzumab works when given with lenalidomide as maintenance therapy after transplant in patients with newly diagnosed multiple myeloma who underwent transplant using their own stem cells (autologous transplant). Maintenance therapy is treatment that is given to ...
What is the current status of trial NCT02420860?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2015-04-14. Estimated completion is 2027-04-30.
What conditions does trial NCT02420860 study?
This clinical trial studies the following conditions: Plasma Cell Myeloma, Hematopoietic Cell Transplantation Recipient.
What interventions are being tested in trial NCT02420860?
The interventions under investigation include: Questionnaire Administration (OTHER), Lenalidomide (DRUG), Elotuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02420860?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02420860 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plasma Cell Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02420860's enrollment target sits among peer trials
113 11th of 32 higher than 22 of 32 other Plasma Cell Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plasma Cell Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
RECRUITING · Phase 2
-
Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 2
-
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Lenalidomide Maintenance in Plasma Cell Myeloma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00748254 · 113 participants
Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
- NCT04753190 · 113 participants · NA
Light Timing Study
- NCT05799248 · 113 participants · Phase 3
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
- NCT07216105 · 113 participants · Phase 1
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI